How do genetic changes contribute to acute lymphoblastic leukemia development?

Know ALL was pleased to speak to Charles Mulligan, St Jude Children's Research Hospital, Memphis, US. We asked, How do genetic changes contribute to acute lymphoblastic leukemia development?

Why do we have so many different types of acute lymphoblastic leukemia?

Know ALL was pleased to speak to Anthony Moorman, Newcastle University, Newcastle upon Tyne, UK. We asked, Why do we have so many different types of acute lymphoblastic leukemia?

What treatment strategies are being used in relapsed acute lymphoblastic leukemia?

During the European School of Haematology (ESH) 2nd Translational Research Conference: Acute Lymphoblastic Leukaemia, Know ALL spoke to Elias Jabbour, MD Anderson Cancer Center, Houston, US.

What do we know about acute lymphoblastic leukemia development and treatment?

Know ALL was pleased to speak to Charles Mulligan, St Jude Children's Research Hospital, Memphis, US. We asked, What do we know about acute lymphoblastic leukemia development and treatment?

What supportive care is needed for patients receiving CAR T-cell therapy?

During the 4th European CAR T-cell Meeting, Know ALL was pleased to speak with Natacha Bolaños, Lymphoma Coalition, Madrid, ES. We asked, What supportive care is needed for patients receiving CAR T-cell therapy?

What is Ph-like acute lymphoblastic leukemia, and how is it treated?

During ESH 3rd How to Diagnose and Treat Acute Leukaemias ,Know ALL was pleased to speak with Emily Curran, University of Cincinnati, Cincinnati, US. We asked, What is Ph-like acute lymphoblastic leukemia, and how is it treated?

What is MRD, and why is it important in acute lymphoblastic leukemia?

During the ESH 3rd How to Diagnose and Treat Acute Leukaemias, Know ALL spoke with Sebastian Giebel, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, PL. We asked, What is measurable residual disease (MRD), and why is it important in acute lymphoblastic leukemia?

How was your ALL treatment journey, and what were the most challenging parts of it?

Know ALL was pleased to speak to Coralie Hykes, San Francisco, California, US. We asked, How was your acute lymphoblastic leukemia treatment journey, and what were the most challenging parts of it?

How was your diagnosis and how are you coping with the challenges?

Know ALL was pleased to speak to Sue Futeral, Baltimore, Maryland, US. We asked, How was your diagnosis and how are you coping with the challenges?

What are the long-term treatment effects in ALL?

As part of the Know ALL spring ambassador meeting, our expert panel engaged in an informative discussion on some of the long-term treatment effects facing survivors of childhood acute lymphoblastic leukemia

How I treat relapsed or refractory ALL

At the 2023 Know ALL Community Meeting, Dr. Nicola Gökbuget, University Hospital Frankfurt, Frankfurt, DE, delivers an expert-led session on the topic of how I treat relapsed or refractory ALL.

My treatment experience

At the 2023 Know ALL Community Meeting, Sophie Wheldon delivers a patient-led session on the topic of my treatment experience.

How I treat newly diagnosed ALL

At the 2023 Know ALL Community Meeting, Dr. Nicholas Short, MD Anderson Cancer Center, Houston, US, delivers an expert-led session on the topic of how I treat newly diagnosed ALL.

What was your ALL subtype and what were the challenges you faced?

Know ALL was pleased to speak to Co-Chair Jaymz Goodman, UK. We asked, what was your ALL subtype and what were the challenges you faced?

What was your ALL subtype and what were the challenges you faced?

Know ALL was pleased to speak to Pete Jerrett, UK. We asked, what was your ALL subtype and what were the challenges you faced?

Today is World ALL Day!

Know ALL co-chair, Jaymz Goodman, raises awareness of World ALL Day (WAD) 2023 and shares details on how you can get involved this year with Know ALL's WAD Campaign.

Introduction and background to health inequality

During this recent interactive workshop, Know ALL co-chair Zack Pemberton-Whiteley, Chair of the Acute Leukemia Advocates Network and CEO of Leukaemia Care, delivers a presentation on health inequality and global health equity.

Challenges for patients with ALL undergoing long-term treatment

During the recent ambassador meeting, co-chair and patient Jaymz Goodman led a discussion on the challenges faced by patients with ALL undergoing long-term treatment.

Challenges for caregivers supporting patients with ALL undergoing long-term treatment

During the recent ambassador meeting, our ambassadors discussed the challenges for caregivers supporting patients with ALL undergoing long-term treatment.

Clinical trials in acute lymphoblastic leukemia

Know ALL was pleased to speak to Michael Osborn, Women's and Children's Hospital, Adelaide, AU. We asked, are there any clinical trials focusing on relapse in ALL, what is the future of CAR T-cell therapy clinical trials for ALL, are there any novel agents currently being investigated for ALL, and how can patients get involved in clinical trials?

What would make ALL research more accessible to patients and their caregivers?

KnowALL was pleased to speak to Anthony Moorman, Newcastle University, Newcastle upon Tyne, UK. We asked, What would make ALL research more accessible to patients and their caregivers?

How does access to healthcare affect the patient journey with ALL?

Know ALL was pleased to speak to Yervand Hakobyan, Armenian Hematology Association, Armenia. We asked, "How does access to healthcare affect the patient journey with ALL?"

Clinical trials: What are they, where are they, and how can they support us as patients?

During the recent ambassador meeting, Mark Litzow delivered a presentation on clinical trials in acute lymphoblastic leukemia (ALL).

Diagnosis and hindsight: What early signs and symptoms do you wish you or your HCP had spotted?

During the recent ambassador meeting, our ambassador Peter Jerrett chairs a discussion with our other ambassadors on the early signs and symptoms of acute lymphoblastic leukemia (ALL), including those that are easily missed or overlooked.

What factors affect acute lymphoblastic leukemia survivorship?

For World ALL Day 2024, Anthony Moorman, Newcastle University, Newcastle upon Tyne, UK, discussed the factors that influence survivorship in acute lymphoblastic leukemia.

How do you provide emotional support to a pediatric patient with acute lymphoblastic leukemia?

For World ALL Day 2024, Vanessa Marais, a clinical psychologist from South Africa, shared insights on how to provide emotional support to pediatric patients with acute lymphoblastic leukemia.

What are the benefits of support groups and how effective are they?

For World ALL Day 2024, Lidija Pecova, HEMA-ONKO, North Macedonia, discussed the importance of support groups for patients and caregivers, including the benefits of attending.

How do you provide emotional support to an adult patient with acute lymphoblastic leukemia?

For World ALL Day 2024, Vanessa Marais, a clinical psychologist from South Africa, shared insights on how to provide emotional support to adult patients with acute lymphoblastic leukemia.

What is the most difficult part of being a caregiver for someone with acute lymphoblastic leukemia?

Know ALL was pleased to speak to Sharon Cohan, a patient advocate from the Leukemia & Lymphoma Society, US. We asked,What is the most difficult part of being a caregiver for someone with acute lymphoblastic leukemia (ALL)?

What is your experience of supportive care at the end of treatment?

Know ALL was pleased to speak to Pete Jerrett, UK. We asked, What was your experience of supportive care at the end of treatment and how can side effects be reduced?

Collaborating to manage immunotherapy side effects: Patient and HCP perspectives

During the recent Know ALL Ambassador Meeting, Dr Mark Litzow and Jess Olson, a Know ALL ambassador and patient, led a discussion on how healthcare professionals and patients can collaborate to manage side effects associated with immunotherapy in acute lymphoblastic leukemia (ALL).

How is blinatumomab used to treat ALL today, and how might it be used in the future?

Know ALL was pleased to speak to Mark Litzow, Mayo Clinic, Rochester, US. We asked, How is blinatumomab used to treat acute lymphoblastic leukemia (ALL)today, and how might it be used in the future?

How to talk to your loved ones about your diagnosis

For World ALL Day 2025, Know ALL spoke with Sharon Cohan, a social worker and patient advocate, from the Leukemia & Lymphoma Society, New York, US. We asked about how to talk to your loved ones about your diagnosis with acute lymphoblastic leukemia.

What does survivorship mean to you, and what advice would you give someone just starting their journey with ALL?

For World ALL Day 2025, Know ALL spoke to Jaymz Goodman, Chair of Know ALL and previously a patient with acute lymphoblastic leukemia. We asked, What does survivorship mean to you, and what advice would you give someone just starting their journey with acute lymphoblastic leukemia?

What questions should I ask my doctor during my initial appointment following a diagnosis of ALL?

For World ALL Day 2025, Know ALL spoke with Peter Jerrett, Know ALL Ambassador and patient from London, UK. We asked, What questions should I ask my doctor during my initial appointment?

How is ALL diagnosed, and what tests should I expect?

For World ALL Day 2025, Know ALL spoke to Mark Litzow, Mayo Clinic, Rochester, US. We asked, How is acute lymphoblastic leukemia (ALL) diagnosed, and what tests should I expect?

How likely is relapse in ALL, and what are the treatment options?

For World ALL Day 2025, Know ALL spoke to André Baruchel, Hôpital Robert-Debré andHôpital Saint-Louis, Paris, FR. We asked, How likely is relapse in ALL, and what are the treatment options?

What side effects can you expect during treatment for ALL, what impact might they have on daily life, and how can you manage them?

For World ALL Day 2025, Know ALL spoke to Coralie Hykes, Know ALL Ambassador and previously a patient with ALL. We asked, What side effects can you expect during treatment for ALL, what impact might they have on daily life, and how can you manage them?

What are clinical trials, and why do we need them for ALL?

For World ALL Day 2025, Know ALL spoke to Robin Foà, an emeritus Professor of Hematology from Sapienza University of Rome, Rome, IT. We asked, What are clinical trials, and why do we need them for ALL?

What is the difference between chemotherapy and immunotherapy, and which one is best for me?

For World ALL Day 2025, Know ALL spoke to Ibrahim Aldoss, City of Hope Comprehensive Cancer Center, Duarte, US. We asked, What is the difference between chemotherapy and immunotherapy, and which one is best for me?

What are signs and symptoms for ALL, and which ones may get overlooked?

For World ALL Day 2025, Know ALL spoke to Dr Elias Jabbour, MD Anderson Cancer Center, Houston, US. We asked, What are the signs and symptoms of acute lymphoblastic leukemia (ALL), and which ones might get overlooked?

What does remission mean in ALL?

For World ALL Day 2025, Know ALL spoke to Yervand Hakobyan, Armenian Hematology Association, Yerevan, AM. We asked, What does remission mean in acute lymphoblastic leukemia (ALL)?

What can patients expect when joining a clinical trial?

Know ALL was pleased to speak with Lizzie Dean, a patient with acute myeloid leukemia (AML) and patient ambassador for Know AML, and Hayley Ellis, senior hematology research nurse, Queen Elizabeth Hospital, Birmingham, UK. They discussed: “What can patients expect when joining a clinical trial?”